The treatment of scabies with ivermectin
- PMID: 7776990
- DOI: 10.1056/NEJM199507063330105
The treatment of scabies with ivermectin
Abstract
Background: Ivermectin is an anthelmintic agent that has been a safe, effective treatment for onchocerciasis (river blindness) when given in a single oral dose of 150 to 200 micrograms per kilogram of body weight. Anecdotal reports of improvement in patients who suffered from infestation with the mite Sarcoptes scabiei suggest that the ectoparasitic disease scabies might be treated with ivermectin.
Methods: We conducted an open-label study in which ivermectin was administered in a single oral dose of 200 micrograms per kilogram to 11 otherwise healthy patients with scabies and to 11 patients with scabies who were also infected with the human immunodeficiency virus (HIV), 7 of whom had the acquired immunodeficiency syndrome. All patients received a full physical and dermatologic examination; scrapings from the skin of all patients tested positive for scabies. Patients were reexamined two and four weeks after treatment, when the scrapings for scabies were repeated. The patients used no other scabicides during the 30 days before ivermectin treatment or during the 4-week study period.
Results: None of the 11 otherwise healthy patients had evidence of scabies four weeks after a single dose of ivermectin. Of the 11 HIV-infected patients, 2 had < or = 10 scabies lesions before treatment, 3 had 11 to 49 lesions, 4 had > or = 50 lesions, and 2 had heavily crusted skin lesions. In eight of the patients the scabies was cured after a single dose of ivermectin. Two patients received a second dose two weeks after the first. Ten of the 11 patients with HIV infection (91 percent) had no evidence of scabies four weeks after their first treatment with ivermectin.
Conclusions: The anthelmintic agent ivermectin, given in a single oral dose, is an effective treatment for scabies in otherwise healthy patients and in many patients with HIV infection.
Similar articles
-
Variable response of crusted scabies to oral ivermectin: report on eight Egyptian patients.J Eur Acad Dermatol Venereol. 2009 Jul;23(7):793-7. doi: 10.1111/j.1468-3083.2009.03177.x. Epub 2009 Mar 6. J Eur Acad Dermatol Venereol. 2009. PMID: 19309428
-
Efficacy and tolerance of oral ivermectin in scabies.J Eur Acad Dermatol Venereol. 1998 Nov;11(3):247-51. J Eur Acad Dermatol Venereol. 1998. PMID: 9883437
-
Oral ivermectin for the treatment and prophylaxis of scabies in prison.J Dermatolog Treat. 2005 Aug;16(3):138-41. doi: 10.1080/09546630510041277. J Dermatolog Treat. 2005. PMID: 16096178
-
[Crusted scabies in Dakar apropos of 11 cases seen in a year].Dakar Med. 1999;44(2):243-5. Dakar Med. 1999. PMID: 11957295 Review. French.
-
Current trend in ivermectin usage for scabies.J Drugs Dermatol. 2003 Aug;2(4):397-401. J Drugs Dermatol. 2003. PMID: 12884462 Review.
Cited by
-
Scabies: more than just an irritation.Postgrad Med J. 2004 Jul;80(945):382-7. doi: 10.1136/pgmj.2003.014563. Postgrad Med J. 2004. PMID: 15254301 Free PMC article. Review.
-
Scabies community prevalence and mass drug administration in two Fijian villages.Int J Dermatol. 2014 Jun;53(6):739-45. doi: 10.1111/ijd.12353. Epub 2013 Oct 29. Int J Dermatol. 2014. PMID: 24168177 Free PMC article. Clinical Trial.
-
A risk-benefit assessment of agents used in the treatment of scabies.Drug Saf. 1996 Jun;14(6):386-93. doi: 10.2165/00002018-199614060-00004. Drug Saf. 1996. PMID: 8828016 Review.
-
Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies.Indian J Pharmacol. 2009 Feb;41(1):9-14. doi: 10.4103/0253-7613.48882. Indian J Pharmacol. 2009. PMID: 20177574 Free PMC article.
-
Update on parasitic dermatoses.An Bras Dermatol. 2020 Jan-Feb;95(1):1-14. doi: 10.1016/j.abd.2019.12.001. Epub 2019 Dec 31. An Bras Dermatol. 2020. PMID: 32001061 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical